Bayesian Capital Management, LP Mannkind Corp Transaction History

Bayesian Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$3.25 - $5.27 $4,225 - $6,850	-1,300 Reduced 2.24%	56,809 $257,000
Q4 2023 Feb 14, 2024	BUY	$3.34 - $4.29 $84,532 - $108,575	25,309 Added 77.16%	58,109 $211,000
Q3 2023 Nov 14, 2023	BUY	$3.91 - $5.45 $128,248 - $178,760	32,800 New	32,800 $135,000
Q3 2022 Nov 14, 2022	BUY	$2.99 - $4.35 $162,058 - $235,769	54,200 Added 85.9%	117,300 $362,000
Q2 2022 Aug 15, 2022	BUY	$2.67 - $4.77 $168,477 - $300,987	63,100 New	63,100 $240,000

255

150M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.44B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.